Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Salivary Biomarkers Detected for Cancer

By LabMedica International staff writers
Posted on 12 Sep 2011
A saliva test has been developed that can measure the amount of potential carcinogens bound to a person's DNA that will help determine their risk for cancer. More...


Tandem mass spectrometry was used to detect DNA adducts that form when a potentially cancer-causing substance is chemically attached to a strand of DNA, which may interfere with the action of genes involved in health and disease.

Scientists at National Chung Cheng University (Ming-Hsiung, Taiwan ROC) measures the levels of five key DNA adducts, including some that form as a result of cigarette smoking. Stable isotopomers of the analytes were added to DNA isolated from human saliva as internal standards. These were then subjected to enzyme hydrolysis, and enriched by a solid-phase extraction column before analysis by the nanoflow liquid chromatography-nanospray ionization tandem mass spectrometry under the selected reaction-monitoring mode.

Only 5 µg of DNA sample was analyzed for simultaneous quantification of these adducts. The easy accessibility and availability of saliva and the requirement for the small amount of DNA samples make this assay clinically feasible as noninvasive biomarkers for DNA damage resulting from oxidative stress. Traditionally, DNA for such tests had to be obtained by taking a blood sample and processing the white blood cells, which contain large amounts of the genetic material. More recently, however, scientists found that DNA samples could be obtained more conveniently from saliva. The DNA is present in white blood cells found naturally in saliva and from cells shed from the lining of the mouth. DNA adducts are induced by known carcinogens and the presence of such an adduct indicates prior exposure to a potential carcinogen, but does not by itself indicate the presence of cancer.

Hauh-Jyun Candy Chen, PhD, who led the research team, said, "The test measures the amount of damaged DNA in a person's body. This is very important because such damaged DNA we call this 'DNA adducts' is a biomarker that may help doctors diagnose diseases, monitor how effective a treatment is and also recommend things high-risk patients can do to reduce the chances of actually getting a disease." The study was presented on August 31, 2011, at the 242nd National Meeting & Exposition of the American Chemical Society held in Denver (CO, USA).

Related Links:

National Chung Cheng University





Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hematology Consumables
Bioblood Devices
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.